API
< Back to all clusters
[BUSINESS] · South Korea · 3 sources

started · updated

J INTS BIO to develop KRAS targeted cancer therapy using AI

J INTS BIO has launched the development of a new pipeline for KRAS G12D mutation lung cancer therapies. Supported by a 3 billion won research grant from the Ministry of SMEs and Startups through the Scale-up TIPS program, the company aims to secure IND approval by 2027.

The development process utilizes the company’s proprietary AI platform, JIN-NOVA, to design small molecule inhibitors. This approach integrates patient multi-omics data to enhance the discovery of drug candidates. The research project is a collaborative effort involving J INTS BIO as the lead organization, with the Daegu Gyeongbuk Institute of Science and Technology (DGIST) and Yonsei University serving as joint research partners.

While treatments for the G12C mutation exist, there are currently no approved therapies specifically targeting the G12D mutation. J INTS BIO intends to use the data gathered during this process to further refine the JIN-NOVA platform for future drug discovery pipelines.

Entities

DGIST · J INTS BIO · JIN-NOVA · Ministry of SMEs and Startups · Yonsei University